Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › atogepant

atogepant

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of atogepant

6 trials tracked of atogepant: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 230 citations.

6Trials tracked
6Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 5
  1. Phase 3 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Completed · 230 cited
  2. Phase 3 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Completed · 36 cited
  3. Phase 3 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Completed · 27 cited
  4. Phase 4 Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Completed · 11 cited
  5. Phase 3 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Completed · 10 cited
  6. Phase 3 Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bayesian network meta-analysis compares CGRP therapies for episodic migraine
Neurology Meta-analysis
Bayesian network meta-analysis compares CGRP therapies for episodic migraine New migraine drugs show big benefits over placebo for monthly attack counts
This Bayesian network meta-analysis synthesized evidence on six CGRP-targeted therapies for episodic migraine. It found that monoclonal anti…
New migraine drugs cut monthly attacks more than placebo, with injectables slightly better than pills for some people.
medRxiv May 25, 2026
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA
Drug Pipeline Phase III
Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Apr 18, 2026